In both populations, there was a higher proportion of patients receiving breast cancer chemotherapy among those receiving G-CSF than those not receiving G-CSF (commercially insured: 26 189 patients [66.1%] vs 9538 patients [20.3%]; Medicare: 4566 patients [36.4%] vs 1817 patients [9.2%]). Here, CSF3 is linked to breast cancer.